Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Arcus BiosciencesJohnson & Johnson
Last price
$24.32$261.01
Currency
USD
USD
$3B$618B
-29.73
-$3.86$8.63
0.810.23
0$5.28
02.09%
Sector
HealthHealth
Employees
601138,200
Ticker
$RCUS$JNJ
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $RCUS or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.